8-K: Cocrystal Pharma Highlights Norovirus Antiviral CDI-988

Cocrystal Pharma announced its President and co-CEO presented positive Phase 1 data for its lead norovirus antiviral candidate, CDI-988, at a major scientific conference.

Summary

• Cocrystal Pharma's President and co-CEO, Dr. Sam Lee, presented on the company's lead pan-viral protease inhibitor, CDI-988, at the 9th International Calicivirus Conference held from September 7-11, 2025.
• CDI-988 is being developed as a potential first oral antiviral for the prevention and treatment of norovirus infection.
• The company recently completed its Phase 1 study for CDI-988 and received U.S. Food and Drug Administration (FDA) Investigation New Drug (IND) clearance for the next study.
• CDI-988 demonstrated a favorable safety profile in human intestinal tissue and high exposure in the small intestine, suggesting a potential GI-targeted norovirus antiviral.
• In vitro data showed broad-spectrum antiviral activity against multiple norovirus genogroups, including GII.4 and GII.17, which are responsible for the majority of circulating infections.
• Cocrystal Pharma also announced FDA authorization to proceed with a Phase 1b human challenge study for CDI-988, which is expected to begin before year-end 2025.

Sentiment

Score: 8

Explanation: The filing reports significant positive clinical and regulatory milestones for a lead drug candidate targeting a large unmet medical need, indicating strong progress in its development. The risks mentioned are standard for clinical-stage biotech.

Positives

• CDI-988 represents a potential first oral antiviral for norovirus infection, addressing a significant unmet medical need.
• The completion of the Phase 1 study and FDA IND clearance for the next study are significant clinical development milestones.
• CDI-988 demonstrated a favorable safety and tolerability profile in Phase 1, with no serious adverse events reported.
• The drug candidate showed high exposure in the small intestine and a favorable safety profile in human intestinal tissue, the primary site of norovirus infection.
• Broad-spectrum antiviral activity against major norovirus genogroups (GII.4 and GII.17) suggests wide potential applicability.
• FDA authorization to proceed with a Phase 1b human challenge study indicates positive regulatory progress and confidence in the drug candidate.

Risks

• Risks and uncertainties arising from the ability of the clinical research organization to recruit volunteers for, and to otherwise proceed with, the challenge study.
• Risks relating to the contract manufacturing organization's ability to produce the products needed for the study.
• Risks associated with the company's ability to obtain regulatory approval for and proceed with clinical trials.
• Liquidity needs of the company.
• Actual results could differ from forward-looking statements due to various factors, and the company undertakes no obligation to publicly update such statements.

Future Outlook

The company plans to initiate a Phase 1b human challenge study for CDI-988 before year-end 2025 to evaluate its potential as a norovirus prophylaxis and treatment. Management believes CDI-988 has the potential to be the first oral antiviral for norovirus infection, addressing a significant unmet medical need.

Management Comments

• "It was an honor to share highlights of our CDI-988 Phase 1 data with global norovirus experts at the leading calicivirus scientific meeting." Dr. Sam Lee, President and co-CEO.
• "The recent completion of Phase 1 study and U.S. Food and Drug Administrations (FDA) Investigation New Drug (IND) clearance for the next study mark significant milestones for our clinical development of CDI-988." Dr. Sam Lee.

Industry Context

Norovirus is the leading cause of viral gastroenteritis worldwide, responsible for an estimated $60 billion in global direct healthcare costs and lost productivity. The development of CDI-988 as a potential first oral antiviral addresses a significant unmet medical need in a large global market, positioning Cocrystal Pharma as a key player in antiviral drug development for caliciviruses. The International Calicivirus Conference is a triennial event that unites global scientists, indicating the importance of such scientific forums for presenting groundbreaking research in the field.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical and regulatory progress for a key drug candidate, potentially increasing company value.
• Patients: Potential for a first oral antiviral treatment for norovirus, addressing a major global health burden.
• Healthcare Providers: New tool for prevention and treatment of norovirus infections, which are highly contagious and costly.
• Employees: Continued progress in drug development could lead to job security and growth opportunities.

Next Steps

• Initiate a Phase 1b human challenge study for CDI-988 before year-end 2025.
• Continue clinical development of CDI-988 as a potential norovirus prophylaxis and treatment.

Key Dates

Recommendation

The company has achieved significant clinical and regulatory milestones for CDI-988, a potential first-in-class oral antiviral for norovirus, a disease with a substantial global burden and no current specific treatment. The successful completion of Phase 1, FDA IND clearance, and authorization for a Phase 1b human challenge study de-risk the program considerably. These advancements, coupled with a favorable safety profile and broad-spectrum activity, position Cocrystal Pharma for strong future growth, making it an attractive investment for long-term investors.

Keywords

Cocrystal Pharma, CDI-988, Norovirus, Antiviral, Phase 1, Clinical Trial, FDA, Biotechnology, Drug Development, Gastroenteritis, Protease Inhibitor